TP53 and colorectal carcinoma: Similar to 5-FU, oxaliplatin (OXA) and irinotecan (IRI), the alternative p53 activating chemotherapies for CRC patients34–37, significantly increased the β-catenin level and expressions of WNT3 and CSC markers (Supplementary Fig. 7a–c).